Ultimovacs ASA

OB:ULTI Stock Report

Market Cap: NOK 74.3m

Ultimovacs Management

Management criteria checks 3/4

Ultimovacs' CEO is Carlos de Sousa, appointed in Jun 2020, has a tenure of 4.42 years. total yearly compensation is NOK6.50M, comprised of 74.5% salary and 25.5% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth NOK56.28K. The average tenure of the management team and the board of directors is 5.8 years and 9.8 years respectively.

Key information

Carlos de Sousa

Chief executive officer

NOK 6.5m

Total compensation

CEO salary percentage74.5%
CEO tenure4.4yrs
CEO ownership0.08%
Management average tenure5.8yrs
Board average tenure9.8yrs

Recent management updates

Recent updates

Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Feb 21
Companies Like Ultimovacs (OB:ULTI) Can Afford To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Oct 26
Ultimovacs (OB:ULTI) Is In A Strong Position To Grow Its Business

Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Oct 05
Companies Like Ultimovacs (OB:ULTI) Are In A Position To Invest In Growth

Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

May 19
Ultimovacs (OB:ULTI) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

Jul 27
Here's Why We're Not At All Concerned With Ultimovacs' (OB:ULTI) Cash Burn Situation

We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Mar 23
We're Hopeful That Ultimovacs (OB:ULTI) Will Use Its Cash Wisely

Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

Feb 13
Have Insiders Sold Ultimovacs ASA (OB:ULTI) Shares Recently?

CEO Compensation Analysis

How has Carlos de Sousa's remuneration changed compared to Ultimovacs's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NOK 149m

Jun 30 2024n/an/a

-NOK 179m

Mar 31 2024n/an/a

-NOK 178m

Dec 31 2023NOK 7mNOK 5m

-NOK 189m

Sep 30 2023n/an/a

-NOK 204m

Jun 30 2023n/an/a

-NOK 186m

Mar 31 2023n/an/a

-NOK 165m

Dec 31 2022NOK 8mNOK 5m

-NOK 168m

Sep 30 2022n/an/a

-NOK 148m

Jun 30 2022n/an/a

-NOK 153m

Mar 31 2022n/an/a

-NOK 168m

Dec 31 2021n/an/a

-NOK 165m

Sep 30 2021n/an/a

-NOK 138m

Jun 30 2021n/an/a

-NOK 126m

Mar 31 2021n/an/a

-NOK 124m

Dec 31 2020NOK 5mNOK 3m

-NOK 121m

Compensation vs Market: Carlos's total compensation ($USD587.17K) is above average for companies of similar size in the Norwegian market ($USD300.00K).

Compensation vs Earnings: Carlos's compensation has been consistent with company performance over the past year.

CEO

Carlos de Sousa (66 yo)

4.4yrs

Tenure

NOK 6,504,000

Compensation

Dr. Carlos de Sousa serves as Chief Executive Officer at Ultimovacs ASA since June 01, 2020. Dr. de Sousa served as Chief Executive Officer of Immunicum AB (publ) since October 1, 2016 until December 13, 2...

Leadership Team

NamePositionTenureCompensationOwnership
Carlos de Sousa
Chief Executive Officer4.4yrsNOK 6.50m0.076%
NOK 56.3k
Hans Eid
Chief Financial Officer9yrsNOK 4.41m0.17%
NOK 123.6k
Ingunn Westgaard
Head of Researchno dataNOK 2.57mno data
Audun Tornes
Chief Technology Officer3.8yrsNOK 2.92mno data
Jens Egil Bjorheim
Chief Medical Officer8.4yrsNOK 4.29mno data
Oivind Foss
Head of Clinical Operations7.3yrsNOK 2.71mno data
Orla Mc Callion
Head of Regulatory Affairs & QA3.1yrsNOK 2.37mno data
Torill Trones
Head of Officeno datano datano data

5.8yrs

Average Tenure

Experienced Management: ULTI's management team is seasoned and experienced (5.8 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Jonas Einarsson
Independent Chairman13.8yrsNOK 450.00k0.015%
NOK 11.4k
Kari Gronas
Independent Director5.8yrsNOK 250.00k0.019%
NOK 14.3k
Henrik Schussler
Director9.8yrsNOK 250.00kno data

9.8yrs

Average Tenure

61yo

Average Age

Experienced Board: ULTI's board of directors are considered experienced (9.8 years average tenure).